Company / Net Income
GT Biopharma, Inc. Net Income History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$38.6M
FY2020
5-year range
-$38.6M / $9.8M
FY2016-FY2020
Trend
-495.6%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Net Income changed -496% YoY in FY2020, a notable deviation from the 7-year average annual change of -710%.
Based on SEC 10-K filings.
-$39M in FY2020.
Declined from -$33M to -$39M over the past 4 years.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2020, net income decreased 495.6% year-over-year.
- Peak net income was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | -$38.6M | -495.6% |
| FY2017 | $9.8M | +129.8% |
| FY2016 | -$32.7M | -39.3% |
| FY2015 | -$23.5M | -4588.4% |
| FY2014 | -$501.0K | +90.3% |
| FY2013 | -$5.2M | -39.8% |
| FY2012 | -$3.7M | -23.5% |
| FY2011 | -$3.0M | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026